Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
biochemistry, genetics and molecular biology
Effects of Gingko biloba supplementation in Alzheimer's disease patients receiving cholinesterase inhibitors: Data from the ICTUS study
Phytomedicine, Volume 21, No. 6, Year 2014
Notification
URL copied to clipboard!
Description
Ginkgo biloba (Gb) is currently the most investigated and adopted herbal remedy for cognitive disorders and Alzheimer's disease (AD). Nevertheless, its efficacy in the prevention and treatment of dementia still remains controversial. Specifically, the added effects of Gb in subjects already receiving "conventional" anti-dementia treatments have been to date very scarcely investigated. We evaluated whether the use of Gb is associated with additional cognitive and functional benefit in AD patients already in treatment with cholinesterase inhibitors (ChEIs). Data are from mild to moderate AD patients under ChEI treatment recruited in the Impact of Cholinergic Treatment USe (ICTUS) study. Mixed model analyses were performed to measure six-monthly modifications in the Mini Mental State Examination (MMSE), the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog) subscale score, and the Activities of Daily Living (ADL) scale over a follow-up of 1 year according to the additional Gb supplementation. A total of 828 subjects were considered for the present analyses. Significantly different modifications at the MMSE score over the 12-month follow-up were reported between patients on combined therapy compared to those only taking ChEIs. On the contrary, the modification of the ADAS-Cog score between the two groups did not show statistically significant differences, although similar trends were noticed. No significant modifications of the two adopted outcome measures were observed at the mid-term 6-month evaluation. The modifications over time of the ADL score did not show statistically significant differences between the two groups of interest. Our findings suggest that Gb may provide some added cognitive benefits in AD patients already under ChEIs treatment. The clinical meaningfulness of such effects remains to be confirmed and clarified. © 2014 Elsevier GmbH.
Authors & Co-Authors
Canevelli, Marco
Italy, Rome
Faculty of Medicine and Psychology
France, Toulouse
Chu de Toulouse
Adali, N.
France, Toulouse
Chu de Toulouse
Morocco, Marakech
Chu Mohammed-vi
Kelaiditi, Eirini
France, Toulouse
Chu de Toulouse
Cantet, Christelle
France, Toulouse
Chu de Toulouse
France, Paris
Inserm
France, Toulouse
Université Toulouse Iii - Paul Sabatier
Ousset, Pierre Jean
France, Toulouse
Chu de Toulouse
Cesari, Matteo
France, Toulouse
Chu de Toulouse
France, Paris
Inserm
France, Toulouse
Université Toulouse Iii - Paul Sabatier
Statistics
Citations: 63
Authors: 6
Affiliations: 5
Identifiers
Doi:
10.1016/j.phymed.2014.01.003
ISSN:
09447113
e-ISSN:
1618095X
Research Areas
Mental Health
Study Design
Cohort Study